No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GSK GlaxoSmithKline
- 41.290
- +0.380+0.93%
Trading Apr 26 12:56 ET
84.36BMarket Cap13.76P/E (TTM)
41.290High40.870Low1.12MVolume40.910Open40.910Pre Close46.16MTurnover0.06%Turnover Ratio13.76P/E (Static)2.04BShares43.84052wk High5.05P/B81.32BFloat Cap32.34652wk Low1.43Dividend TTM1.97BShs Float44.360Historical High3.47%Div YieldTTM1.03%Amplitude6.563Historical Low41.108Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
20 Fastest Growing Health Tech Companies in the World
Express News | Glaxosmithkline Sues Pfizer and BioNTech Over Mrna Technology Patents in Covid-19 Vaccines - US Court Filing
CureVac Begins Early Stage Portion of Investigational Vaccine Trial
CureVac (CVAC) said Wednesday it initiated the early stage portion of a broader study into an investigational flu vaccine developed with GSK (GSK). The phase 1 trial is part of a combined phase 1/2 st
Express News | CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus
Express News | CureVac And GSK Will End The Pandemic Preparedness Agreement Jointly Concluded With The Federal Republic Of Germany In April 2022, After Consultation With The German Federal Ministry Of Health
Express News | The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer
Comments
Major acquisition announced YTD in 2024
A look at one of the major acquisition deals YTD…👇
$MRTX
Acquired By: Bristol-Myers Squibb$Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$$GlaxoSmithKline(GSK.US$
$MRTX
Acquired By: Bristol-Myers Squibb$Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$$GlaxoSmithKline(GSK.US$
4
1
$GlaxoSmithKline(GSK.US$ One day up, next 3-4 days will go down again
Goldman Sachs' Chief Global Equity Strategist Peter Oppenheimer finds the GRANOLAS' outperformance impressive on a risk-adjusted basis. They can benefit from the shift towards passive investment as they outperform when passive funds see more inflows.
1
Citi analyst Andrew Baum predicts Blenrep will be a standard care for refractory multiple myeloma patients for the next five years, assuming the DREAMM-8 trial meets its primary goal.
1
GSK's optimistic long-term outlook is driven by the expected launch of at least 12 major products from 2025 in infectious, respiratory disorders and cancer areas. The company's performance and future outlook could suggest a positive trend for the stock.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
MindTrader : are you a FT trader?